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ABSTRACT Zoonotic viruses circulate as swarms in animal reservoirs and can emerge
into human populations, causing epidemics that adversely affect public health. Portable,
safe, and effective vaccine platforms are needed in the context of these outbreak and
emergence situations. In this work, we report the generation and characterization of an
alphavirus replicon vaccine platform based on a non-select agent, attenuated Venezue-
lan equine encephalitis (VEE) virus vaccine, strain 3526 (VRP 3526). Using both norovi-
ruses and coronaviruses as model systems, we demonstrate the utility of the VRP 3526
platform in the generation of recombinant proteins, production of virus-like particles,
and in vivo efficacy as a vaccine against emergent viruses. Importantly, packaging under
biosafety level 2 (BSL2) conditions distinguishes VRP 3526 from previously reported al-
phavirus platforms and makes this approach accessible to the majority of laboratories
around the world. In addition, improved outcomes in the vulnerable aged models as
well as against heterologous challenge suggest improved efficacy compared to that of
previously attenuated VRP approaches. Taking these results together, the VRP 3526 plat-
form represents a safe and highly portable system that can be rapidly deployed
under BSL2 conditions for generation of candidate vaccines against emerging
microbial pathogens.
IMPORTANCE While VEE virus replicon particles provide a robust, established plat-
form for antigen expression and vaccination, its utility has been limited by the re-
quirement for high-containment-level facilities for production and packaging. In this
work, we utilize an attenuated vaccine strain capable of use at lower biocontain-
ment level but retaining the capacity of the wild-type replicon particle. Importantly,
the new replicon platform provides equal protection for aged mice and following
heterologous challenge, which distinguishes it from other attenuated replicon plat-
forms. Together, the new system represents a highly portable, safe system for use in
the context of disease emergence.
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Vaccines represent critical preparedness platforms for protecting overall publichealth. Because many newly discovered viruses originate as zoonotic precursors,
the key antigenic determinants essential for protective immunity remain unknown,
oftentimes until after an outbreak of disease is detected in human populations.
Outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 to
2003 (1, 2) and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 (3, 4)
are examples of new human viruses which emerged from zoonotic precursors and
produce serious disease, especially in aged populations. The recent discovery of SARS
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and MERS-like CoVs circulating in bats further indicate the ongoing threat to human 
populations (5–7). Design of a broadly cross-protective vaccine in such instances is 
dependent upon not only knowledge of the key antigenic determinants but also the 
availability of a rapid-response vaccine platform to easily generate, characterize, and 
successfully apply to vulnerable populations, like the aged (8, 9).
Alphavirus replicon particles (VRPs) based on the Trinidad strain of Venezuelan 
equine encephalitis (VEE) virus are replication incompetent, induce strong mucosal, 
cellular, and humoral immune responses and ensure clinical safety (10–12). VRPs consist 
of the VEE virus replicon RNA encoding the replicase proteins and a 26S promoter from 
which foreign transgenes are expressed (13). As replicon RNAs lack the structural genes, 
helper RNAs are provided in trans to produce infectious particles that infect a wide 
variety of target cell lines and host species, allowing for vaccination against the 
heterologous expressed protein (14–16). The absence of preexisting immunity to VEE 
virus in human populations also provides added utility for the vaccine platform’s use in 
the general population (13, 15, 17, 18).
VRPs based on wild-type VEE virus 3000 as well as attenuated VEE virus 3014 
structural protein coats induce robust immunity against a variety of antigens and have 
proven to be successful vaccine platforms (15, 17, 18). However, concerns have ham-
pered VEE virus 3000-based vaccine applications because of the potential for 
replication-competent wild-type VEE virus infectious particles. Produced by recombi-
nation or from copackaging of helper and replicon RNAs, the VEE virus 3000 VRPs retain 
some risk of wild-type VEE virus infection or disease (19). For increased safety, VRP 
vaccines for human use in preclinical and clinical trials have often employed the 
attenuated VEE virus coat 3014 (14, 18). VEE virus 3014 coat protein differs from the wild 
type by three amino acids which attenuate VEE virus in vivo, possibly by enhancing 
binding to heparin sulfate, thereby leading to accelerated clearance of virus from the 
blood (20). VRPs based on 3014 coat have been shown to be successful in inducing 
immune response and have demonstrated protection in both small- and large-animal 
models of viral disease (8, 17, 18). Furthermore, the attenuated platform provides ease 
of purification for manufacturing processes. Despite this attenuation, the VRP 3014 
platform still retains some risk for VEE virus-mediated disease and as such must be 
packaged and safety tested under biosafety level 3 (BSL3) conditions.
SARS-CoV, MERS-CoV, seasonal and pandemic strains of influenza virus, and other 
pathogens cause disproportionate disease outcomes in the elderly. Mortality rates are 
found to be 50% in SARS-CoV- and MERS-CoV-infected aged individuals (11, 17, 21). 
Thus, vaccination of aged individuals is imperative to reduce the overall morbidity and 
mortality of these pathogens. Previous studies from our laboratory have demonstrated 
that VRP 3014 provides only partial protection from heterologous virus challenge in 
young animals (11, 17). However, it failed to protect aged animals from lethal homol-
ogous and heterologous virus challenge, using SARS-CoV and influenza virus as models 
(11, 17). This incomplete protection and failure to protect immunosenescent animals 
was directly correlated with an inability to induce protective antibody responses in vivo 
(8, 11). In parallel studies, VRP 3000-based vaccines also provided incomplete protec-
tion but significantly reduced lethal disease and serious clinical disease in aged animals 
(17). Thus, the attenuation of VRP 3014 produced a platform less effective in aged 
animals and is therefore less attractive for use in humans, given the expanding aged 
population over the next 2 decades.
In order to improve the replicon vaccine platform, we generated a new VRP system 
utilizing the VEE virus 3526 backbone. VEE virus 3526, a live attenuated vaccine strain, 
is highly immunogenic in primates and horses and is safe when administered by 
intraperitoneal infection (22). VEE virus 3526 contains a cleavage site deletion in E3 and 
a second-site resuscitating mutation in E1, leaving the wild-type E1, E2, and capsid 
sequences intact (23); these mutations are associated with the attenuated phenotype 
observed for this strain (24). In this work, we describe the generation and character-
ization of the VRP platform based on VEE virus vaccine strain 3526. We confirm VRP 
expression of transgenes and the ability to produce virus-like particles for noroviruses.
FIG 1 Characterization of VRP 3526 platform. (A) Schematic of VRP 3526 platform showing replicon gene with reporter gene in pVR21 plasmid. Arrows indicate
the start of 26S subgenomic promoter. (B) Titers of S protein vaccines from V3000, V3526, and V3014 coats determined on BHK cells by an IFA assay. **, P 
0.01; ***, P  0.001 (Student’s t test). (C) Western blot from independent experiments showing expression of SARS-CoV Spike protein from V3526S and V3000S
vaccines in Vero cells. The lower panel shows actin.
In addition, we tested VRP 3526 expressing the SARS-CoV spike glycoprotein, finding 
similar antigen expression of spike expressed from the VRP 3000 system. Similarly, the 
VRP 3526-based SARS spike protected both young and aged mice from lethal disease 
and correlated with no weight loss, reduced viral replication, and generation of 
neutralizing antibodies against homologous and heterologous strains. Importantly, VRP 
3526 spike was equivalent to VRP 3000 spike and superior to VRP 3014 spike in 
protecting aged mice from lethal acute respiratory disease outcomes. Taken together, 
our data demonstrate the highly portable and safe VRP 3526 platform confers a robust 
expression/vaccine system that induces robust immune responses that protect both 
young and aged animal models from lethal challenge.
RESULTS
Construction and characterization of a VRP 3526 vector platform. While alpha-
virus replicon particles based on wild-type VRP 3000 or the attenuated VRP 3014 
surface coats are highly successful vaccine platforms (15, 17, 24, 25), a myriad of 
concerns have limited their use, including select agent/BSL3 containment, reversion, 
and inefficacy of the vaccine platform in vulnerable populations. To overcome these 
issues, we developed a platform that utilizes the VEE virus 3526 vaccine backbone, 
which combines the deletion of the entire furin cleavage site between E3 and E2 with 
a secondary site resuscitating mutation in E1 (23, 26, 27); this attenuated virus packages 
fused E3/E2 protein (PE2), has been used in humans as a vaccine candidate, and is a 
BSL2 pathogen (28, 29). Based on this attenuated VEE virus strain, we generated a new 
VRP vector platform (Fig. 1A). The system uses the sequence of the wild-type VEE 3000 
virus, including the 5= and the 3= untranslated regions (UTR) (13). The structural 
glycoproteins (GPs) for VRP 3526 have a deletion in the furin cleavage site in E3 
(Δ56RKRR59) that attenuates pathogenesis in cell culture and mice; a second mutation 
in the E1 glycoprotein restores efficient growth in BHK cells and prevents reversion to 
virulence through other secondary mutations (23). The glycoprotein genes as well as 
viral capsid gene were inserted into separate helper constructs between the 26S 
subgenomic promoter and the beginning of the 3= UTR. All three plasmids were 
linearized, and RNA transcripts were electroporated into BHK cells. After 24 to 48 h, cell
culture supernatants were collected, the VRPs were purified, and titers were deter-
mined on BHK cells, as described before (17). Consistent with a mild packaging defect, 
VRP 3256 titers ranged between 2.0  107 and 1.0  108 IU/ml, which was about 1 to 
1.5 logs less efficient than the VRP 3000 and VRP 3014 coats (Fig. 1B). Importantly, no 
evidence for viable recombination and electroporation has been observed with the VRP 
3526 system. To date, 47 replicons have been generated and were negative for 
cytopathic effect (CPE) after passages 1 and 2 (data not shown). To further examine the 
possibility for replicative virus, two stocks of VRP 3526 replicons expressing green 
fluorescent protein (GFP) were used to infect Vero cells, subsequently passaged, and 
examined for CPE and GFP expression (Fig. 1C). Following initial passage, Vero cells 
showed robust expression of GFP and minimal CPE at days 1 and 2. After the second 
passage, only a few GFP-positive cells and no CPE were observed over the first 2 days; 
the final passage showed no evidence of GFP or CPE, suggesting that no viable virus 
was present in any of the independent passages. Together, the results argue that 
recombination resulting in viable attenuated VEE 3526 virus is unlikely.
We next characterized antigen expression from the VRP 3526 platform using two 
model antigens: the SARS CoV spike glycoprotein and norovirus (NoV) VP2 capsid 
protein. Using the VRP 3000 platform as a control, we compared the expression of 
SARS-CoV S glycoprotein from the VRP isolated under BSL2 (V3526S) to that isolated 
under BSL3 (V3000S). Following Vero cell infection, two independent experiments 
demonstrated that V3526S produced amounts of SARS-CoV S glycoprotein similar to 
those of V3000S (Fig. 1D). Similarly, NoV VLPs derived from BSL2 V3526-VP1 or BSL3 
V3014-VP1 were indistinguishable from each other in morphology, forming 40-nm 
particles with characteristic cup-shaped surfaces (Fig. 2A and B). In addition, particle 
microstructure integrity was comparable between the 3525 and 3014 VRP platforms 
based on ligand binding (50% effective concentration [EC50] of 1.6 g/ml for V3014-
NoV VLP and EC50 of 1.4 g/ml for V3526-NoV VLP) (Fig. 2C) and mouse polyclonal sera 
(EC50 of 0.65 g/ml for V3014-NoV VLP and EC50 of 0.40 g/ml for V3014-NoV VLP) (Fig. 
2D). Taken together, these data indicate that the VRP 3526 platform yields antigen 
expression similar to that of previous VRP platforms with the added utility of use at a 
lower biosafety level.
Efficacy of VRP 3526 vaccine in young mice. We next analyzed VRP 3526 spike 
(V3526S) vaccine performance in young mice in parallel with VRP 3000 spike (V3000S) 
and VRP 3014 spike (V3014S). Groups of young mice were vaccinated and boosted 3 
weeks later with 1  105 IU of each VRP vaccine and a control VRP 3000 HA (VRP-HA) 
encoding influenza H1N1 hemagglutinin. Blood was collected at 21 days postprime, 
and 3 weeks postboost animals were challenged with a lethal dose of mouse-adapted 
SARS-CoV (105 PFU rMA15) (17, 21, 30). Animals vaccinated with V3000S and V3526S 
were completely protected from SARS-CoV-induced disease, as measured by weight 
loss, morbidity, and death (Fig. 3A). In contrast, V3014S-vaccinated animals lost about 
10% of their body weight by day 3 postinfection and then recovered. VRP-HA-
vaccinated animals lost 20% of their body weight by day 4 postinfection and experi-
enced severe symptoms of acute respiratory distress syndrome (ARDS) disease (Fig. 3A 
and B). Analysis of virus titers at 2 days postinfection revealed that animals vaccinated 
with V3000S and V3526S had minimal viral replication, whereas V3014S-vaccinated 
animals were not protected from viral replication, similar to VRP-HA-vaccinated animals 
(Fig. 3C). While all three VRP coats protected young adult mice from end-stage lung 
disease, mice vaccinated with VRP-HA revealed clear progression to diffuse alveolar 
damage and ARDS, as indicated by the presence of hyaline membranes (Fig. 3D, lower 
right, yellow arrow). In contrast, V3526S-vaccinated mice had minimal airway disease 
and an absence of major lung pathology based on histology scoring (Fig. 3E), similar to 
the V3000S vaccines, and a modest decrease relative to V3014S. Together, the results 
demonstrated that the V3526S platform produced protection similar to that of wild-
type V3000S and V3014S following homologous challenge.
FIG 2 Morphology, ligand binding, and antigenicity of Norwalk virus VLPs produced from V3014 or 
V3526 VRPs. (A and B) Electron micrograph of Norwalk virus VLPs produced from V3014 (A) or V3526 (B) 
VRPs. (C) Carbohydrate ligand binding of Norwalk virus VLPs from V3526 (blue) and V3014 (gray). (D) 
Mouse anti-Norwalk virus polyclonal serum binding to Norwalk virus VLPs. Plotted markers represent the 
means and standard deviations.
VRP 3526 vaccine offers protection from heterologous challenge. We also 
examined the efficacy of V3526S in protecting young mice from heterologous SARS-
CoV challenge. Previous work had shown only modest efficacy of the V3014 platform 
relative to V3000 following heterologous CoV challenge. In this study, V3000S- and 
V3526S-vaccinated animals were challenged with a SARS-CoV chimera encoding a spike 
protein from a heterologous strain, GD03 (17). This mouse-adapted strain had previ-
ously been shown to cause 15% weight loss in young animals and significant airway 
disease (17). Animals immunized with V3000S and V3526S were protected from GD03-
MA15-induced weight loss (Fig. 4A), whereas mock-vaccinated animals lost 15% of 
their body weights. Analysis of lung viral titers 2 days postinfection revealed that viral 
replication was reduced 10,000-fold compared to that of mock-vaccinated animals (Fig. 
4B). Notably, histopathology scoring indicated that neither of the platforms abrogated 
early-stage disease symptoms induced by a heterologous challenge virus (Fig. 4C and 
D, GD03-MA15); both show improvement relative to previous studies with infected, 
unvaccinated mice (17). While paling in comparison to protection from homologous 
challenge (Fig. 3E, MA15), the 3526 platform exceeded the limited efficacy of V3014 in
heterologous challenge (17) and represents an improved, safer approach for vaccine
generation and development.
FIG 3 V3526S protects young mice from lethal SARS-CoV disease induced by homologous challenge. (A and B) Percent weight
loss (A) and survival curve (B) of young mice immunized with S protein-based vaccines from V3000S (black; n  11), V3526S
(blue; n  11), V3014S (gray; n  11), or control (VRP-HA; dashed line; n  11) challenged with 105 PFU of SARS-CoV MA15.
(C) Lung virus titers on 2 days postinfection determined by plaque assay on Vero cells (n  5 for VRP, n  3 for control). The
dashed line represents the limit of detection for plaque assay. Error bars, SEM; ND, none detected; ***, P  0.001 (Student’s
t test). (D) Representative H&E-stained lung sections harvested 4 days postinfection from the indicated vaccine groups showing
lungs, alveoli, and airway vasculature at lower (40) and higher (400) magnification. Note the presence of hyaline
membranes (yellow arrow) in animals vaccinated with VRP-HA, indicating end-stage lung disease, which is absent from V3000S
and V3526S vaccine groups. (E) Scoring of clinical disease in H&E-stained lung sections harvested 4 days postinfection with
V3000S (black), V3526S (blue), V3014S (gray), or control (VRP-HA; white) for airway disease, vascular cuffing, pneumonia, and
diffuse alveolar damage (DAD).
VRP 3526 vaccine platform protects aged mice from lethal SARS-CoV chal-
lenge. We have previously demonstrated that VRP 3000-based, but not VRP 3014-
based, vaccines are effective in protecting aged mice from lethal SARS-CoV challenge 
but not disease (17). We next evaluated the performance of the VRP 3526 vaccine 
platform in protecting aged mice from lethal SARS-CoV challenge. Groups of 1-year-old 
animals were vaccinated and boosted with 1.0  105 IU of each VRP-S vaccine or 
control (VRP-HA). Serum was collected 3 weeks after prime and boost to analyze 
antibody responses, and animals were challenged with 1.0  105 PFU of mouse-
adapted SARS-CoV (17). Both V3526S and V3000S protected aged mice from severe
FIG 4 V3526S protects young mice from SARS-CoV disease induced by heterologous challenge. (A) Percent weight loss of
young mice immunized with S protein-based vaccines from V3000S (black; n  11), V3526S (blue; n  15), or mock (gray;
n  7) immunization and challenge with 105 PFU of rMA15-GD03. (B) Lung virus titers at 2 days postinfection determined
by plaque assay on Vero cells with V3000S (black; n  3), V3526S (blue; n  4), or mock (gray; n  3) immunization. Error
bars indicate standard errors of the means (SEM). ***, P  0.001 (Student’s t test). (C) Representative H&E-stained lung
sections from V3000S- or V3526S-vaccinated mice harvested 4 days postinfection showing lungs, alveoli, and airway
vasculature at lower (40) and higher (400) magnification. (D) Scoring of clinical disease in H&E-stained lung sections
harvested 4 days postinfection from the indicated V3000S (black)- or V3526S (blue)-vaccinated mice for airway disease,
vascular cuffing, pneumonia, and diffuse alveolar damage (DAD). Error bars indicate standard deviations (SD).
SARS-CoV-induced disease, as evidenced by minimal weight loss and lethality (Fig. 5A 
and B). In contrast, animals that received V3014S lost greater than 20% of their body 
weight 4 days postinfection, died, and/or were euthanized (Fig. 5A and B). Lung virus 
titers 2 days postinfection (Fig. 5C) revealed virus replication in V3526S-immunized 
animals was similar to that of V3000S-immunized animals but significantly reduced 
compared to that of V3014S- or VRP-HA-vaccinated animals. Virus replication was 
cleared by day 4 postinfection in V3000S- and V3526S-vaccinated aged animals, 
whereas the viral titers remained high in animals vaccinated with V3014S or VRP-HA. In 
both V3000S- and V3526S-vaccinated animals, lung pathology showed little evidence of 
denuded airway cells or airway debris (Fig. 5D, 400, airways marked by green arrows) 
with minimal inflammatory cell infiltrates (marked by yellow arrows). In contrast, 
animals that received V3014S or VRP-HA showed severe airway inflammation with a 
denuding bronchiolitis (marked by green arrows) with accumulation of apoptotic 
debris and severe peribronchovascular cuffing characterized by high numbers of 
lymphocytes, neutrophils, and macrophages (marked by yellow arrows). Similar to the 
young mouse data, these results indicate superior protection provided by the V3526 S 
platform in aged mice relative to that of V3014S.
Protection in young mice and aged mice correlates with antibody response. We 
next analyzed the serum from young and aged immunized animals. Enzyme-linked 
immunosorbent assay (ELISA) indicated that the SARS-CoV vaccines elicited high IgG
FIG 5 V3526S protects aged mice from lethal SARS-CoV disease. (A to C) Percent weight loss (A) and survival curve (B) of aged mice immunized
with S protein-based vaccines from V3000S (black; n  10), V3526S (blue; n  12), V3014S (gray; n  6), or control (VRP HA; dashed; n  7)
challenge with 105 PFU of SARS-CoV MA15. (C) Lung virus titers at 2 days postinfection and 4 days postinfection, determined by plaque assay
on Vero cells. V3000S (black; n  6 [day 2], 3 [day 4]), V3526S (blue; n  5 [day 2], 3 [day 4]), V3014S (gray, n  3), and control (VRP HA; white;
n  4 [day 2], 3 [day 4]) are shown. Error bars indicate SEM. *, P  0.05; ***, P  0.001 (Student’s t test). (D) Representative H&E-stained lung
sections harvested 4 days postinfection from the indicated vaccine groups showing lungs, alveoli, and airway vasculature at lower (40) and
higher (400) magnification. Note clean airways in V3526S and V3000S groups, as indicated by green arrows, and denuded airways in V3014S
(green arrow). Note the massive inflammatory infiltrates (yellow arrows) in V3014S and VRP-HA groups, which are reduced in V3526S and V3000S
groups.
response to S glycoprotein in young animals, regardless of coat (Fig. 6A). Importantly, 
the V3526S platform elicited serology responses that were equivalent to those mea-
sured with V3000S. V3014S vaccine had slightly but significantly lower antibody titers 
than V3526S and may contribute to reduced protection of young animals from SARS-
CoV-induced disease (Fig. 3A). Examining IgG subtypes, the VRP 3014 platform resulted 
in a mix of both IgG2A, associated with a Th1 response, and IgG1, associated with a Th2 
response (Fig. 6B). In contrast, VRP 3000 produced a strong IgG2A response with 
minimal S-specific IgG1 observed. For VRP 3526, a mixture of IgG2A versus IgG1 
responses was observed. For several mice, IgG2A was dominant (5/9); in contrast, several 
others produced both IgG1 and IgG2A. Notably, V3526S vaccination produced a lower 
magnitude of IgG1 than V3014S and higher IgG2A yields than V3000S. Examining aged 
mice, only V3526S and V3000S elicited high antibody titers (Fig. 6C), whereas V3014S 
and VRP-HA proved to be inefficient in eliciting a detectable serologic response.
FIG 6 V3526S induces high antibody titers that neutralize SARS-CoV. (A) ELISA results showing IgG titers 
to S protein, elicited in young mice following vaccination with V3000S (black), V3526S (blue), V3014S 
(gray), or control VRP-HA (white). (B) Th1/Th2 skewing as measured by IgG2A/IgG1 ratio in young mice.
(C) ELISA results for aged mice following vaccination by indicated vaccine groups. (D) Th1/Th2 skew in 
aged mice as measured by IgG2A/IgG1 ratios. (E and F) Neutralization potential (SARS-CoV) of antibodies 
elicited by indicated vaccine group, i.e., V3000S (black), V3526S (blue), V3014S (gray), or control VRP-HA 
(dashed), in young mice (E) and aged mice (F), as measured by PRNT50 assay. ***, P  0.001 (Student’s 
t test) relative to V3000S and V3526S.
Notably, while both VRP 3526 and 3000 platforms make IgG2A, the response is skewed, 
with more production of IgG1 than is seen with the young mice (Fig. 6D). Together, the
V3526S-vaccinated sera from young mice and aged mice indicate augmented specific
IgG production and skewing toward IgG2A compared to the V3014 platform.
Extending our analysis, we examined neutralizing antibody responses after vacci-
nation, using serum and 50% plaque reduction neutralization assay (PRNT50) against
SARS-CoV (17, 31, 32). PRNT50 analysis indicated that V3526S elicited high neutralizing
antibodies in young mice (PRNT50 values of 1:988) (Fig. 6E), replicating a phenotype
similar to that seen with V3000S (PRNT50 values of 1:679) (Fig. 6E). PRNT50 titers were 
found to be 3-fold lower in V3014S-vaccinated animals (1:286), which likely contrib-
utes to partial protection seen after homologous or heterologous challenge. In addi-
tion, V3526S was still efficient in eliciting neutralizing antibodies in aged mice (PRNT50 
titers of 1:239) (Fig. 6F), similar to what was observed in V3000S-vaccinated animals
(PRNT50 titers of 1:216). In contrast, there was little if any neutralizing response in 
animals vaccinated with V3014S. Together, the results clearly indicate that a neutral-
izing immune response developed after vaccination with the V3256S vaccine and
demonstrate it is the preferred platform for future vaccination strategies.
DISCUSSION
Alphavirus replicon particles based on wild-type VRP 3000 or the attenuated VRP 
3014 surface coats are highly successful vaccine platforms (15, 17, 24, 25). However, 
several disadvantages exist, including (i) select agent restrictions, (ii) packaging and 
safety testing under BSL3 conditions, (iii) potential generation of wild-type VEE virus 
due to RNA recombination, (iv) potential generation of replication competent viruses, 
and (v) failure of VRP 3014 vaccines to protect aged populations against homologous 
and heterologous virus challenge (17). Strategies to circumvent this problem have 
included the use of multiple helper RNAs, alphavirus replicon-based adjuvants, or RNA-
and DNA-based replicon launch platforms in the absence of structural proteins (13, 
33–35). In the manuscript, we have developed and characterized the VRP 3526 platform 
as a highly portable and safe vector platform for expression of novel genes with 
features similar to those of the earlier VRP 3000 and VRP 3014 iterations. Importantly, 
the VRP 3526 platform provided robust protection to vulnerable populations and in the 
context of heterologous challenge. Coupled with increased safety aspects, the VRP 
3526 system represents a significant advance with the potential to be deployed against 
a myriad of emerging microbial pathogens.
Generated at a lower biosafety level, the attenuated VRP 3526 significantly expands 
the number of groups capable of using this platform. Both select agent rules and 
concerns over reversion to wild-type virus had rendered VRP 3000 and VRP 3014 
systems inaccessible to the majority of research groups. By incorporating mutations 
within the backbone and helper constructs, the VRP 3526 platform overcomes these 
safety concerns and allows manipulation at BSL2. In addition, the VRP 3526 platform 
had only modest attenuation in terms of titers relative to controls, likely due to 
incorporated mutations in E1 glycoprotein (13, 23). Importantly, the VRP 3526 platform 
was able to produce high concentrations of both NoV VP1 and SARS-CoV S glycopro-
tein. For SARS-CoV, V3526S produced levels of spike antigen similar to those of V3000S. 
For NoV, the Norwalk VLPs produced within the VRP 3526 system were morphologically 
and antigenically similar to VLPs expressed from VRP 3014, providing a platform for the 
manufacture of VLP vaccine candidates. With only minor differences noted in EC50s of  
polyclonal antibodies, the new platform improves on an invaluable tool needed to 
study genetic determinants of antigenic drift and escape and to design a successful 
norovirus vaccine. Together, the results suggest that the VRP 3526 system can replicate 
VRP 3000 and 3014 as an amplification platform for microbial antigens.
The ability to provide in vivo protection against lethal challenge from human 
pathogens is an appealing feature of the VRP platform and allows for rapid preclinical 
testing of vaccines. In vivo studies in young mice immunized with V3526S demon-
strated clear protection from SARS-CoV challenge. In contrast, the V3014 coat provided 
suboptimal protection in terms of weight loss, viral replication, and damage to the lung 
in young mice. Similarly, the VRP 3526 platform provided protection equivalent to that 
of VRP 3000 in the context of heterologous challenge. While the 3014 platform had 
previously been shown to fail (17), challenge with GD03-MA15 resulted in reduced 
weight loss, viral replication, and disease in mice vaccinated with V3526S. Notably, 
protection correlated with generation of high-titer, antigen-specific antibodies, and the 
VRP 3526 platform produced antibody results similar to those for V3000. Although not 
directly tested, these data suggest that overall B- and T-cell responses are improved in 
VRP 3526 vaccination compared to those in VRP 3014 vaccination. Together, the results 
indicated that the safer VRP 3526 platform outperformed the VRP 3014 platform, 
providing protection following both homologous and heterologous CoV challenges.
Since emerging viruses cause disproportionate disease burdens in the elderly, 
successful vaccination of aged individuals with VRP 3526 represents a key public health 
intervention strategy. V3526S was efficient in protecting aged mice from lethal SARS-
CoV challenge and was indistinguishable from V3000S. Neutralizing antibodies played 
a major role in protection, as evidenced by neutralizing titers of V3526S similar to titers 
measured for V3000S vaccine (17) and 3- to 4-fold higher than thresholds needed for
protective immunity (21). This was also evidenced by the clearance of virus from lungs
at late times postinfection, which in part could be due to T-cell-mediated responses
which have been shown to play a protective role (36, 37). Consistent with our previous
study (11, 17), V3014S vaccines failed to elicit protection in aged individuals, perform-
ing similar to the control, VRP-HA. Importantly, V3526S induced high antibody titers
and neutralization in the aged, which were absent from V3014S and suggest dimin-
ished overall adaptive immune responses. While these responses skewed toward IgG1,
the virus-specific antibody response corresponded with similar results offered by
V3000S and provided a mechanism for protection in aged mice. Together, the data
clearly demonstrate VRP 3526 is an improved, attenuated VRP vaccine platform for
aged mice.
Since the emergence of SARS-CoV at the beginning of the century, zoonotic diseases
have posed a significant threat to global public health. Highly portable and safe vaccine
platforms are key in rapidly responding to these emerging threats. In this study, we
describe a significant advance to the VEE virus replicon particle (VRP) systems that
makes the platform more accessible. The attenuated VRP 3526 system provides an
opportunity to use this resource at a lower biosafety level, and the safety incorporated
within the system does not sacrifice either antigen production or protection under
several vaccine conditions. The overall result is a platform that can be rapidly applied
to new, emerging diseases with efficacy in vulnerable populations and in the context
of heterologous challenge.
MATERIALS AND METHODS
Ethics statement. This study was carried out in strict accordance with the recommendations for care 
and use of animals by the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health. The 
Institutional Animal Care and Use Committee (IACUC) of The University of North Carolina at Chapel Hill 
(UNC; permit number A-3410-01) approved the animal study protocol followed in the manuscript. 
Animals were anesthetized with ketamine and xylazine (per IACUC, UNC, guidelines) for infection and 
were euthanized if the body weight dropped below 80% of starting weight or clinical symptoms 
warranted it per IACUC, UNC, guidelines. UNC is registered with the Centers for Disease Control and 
Prevention to work with select agents, including SARS-CoV.
Virus and cells. The titers of recombinant a SARS-CoV Urbani strain, icSARS (GenBank accession no. 
AY278741), a mouse-adapted derivative, rMA15 (21, 30), and a mouse-adapted derivative encoding a 
heterologous S glycoprotein, rMA15 GD03-S (17), were determined, and they were propagated on Vero 
E6 cells as previously described (17, 38). rMA15 differs from the epidemic strain SARS-CoV Urbani in 6 
amino acids (H133Y nsp5, E269A nsp5, T67A nsp9, A4V nsp13, Y436H spike, and E11K M protein)
(GenBank accession no. AY525636). The GD-03 strain of SARS-CoV was identified from sporadic human 
cases during the second wave of the SARS epidemic in 2004 and is distinct from the 2003 Urbani-derived 
epidemic isolates (11, 17). rMA15 GD03-S was derived from an MA15 molecular clone by replacing the 
MA15 Urbani spike with the GD03-S glycoprotein encoding the Y436H mouse-adapted S mutation (17). 
Vero E6 cells were grown in minimal essential medium (MEM; Invitrogen, Carlsbad, CA) supplemented 
with 10% FetalClone II (HyClone, South Logan, UT) and gentamicin-kanamycin (UNC Tissue Culture 
Facility). All SARS-CoV work was performed in a class II biological safety cabinet in a certified biosafety 
level 3 laboratory containing redundant exhaust fans. Personnel wore Tyvek suits, gloves, and shoe 
covers and used portable air breathing apparatus (PAPR) as described previously (39). All animal work 
was performed in SealSafe HEPA-filtered mouse caging as specified by the manufacturer (Techniplast) 
using IACUC-approved protocols and procedures (40).
Packaging and production of VRPs expressing SARS-CoV glycoproteins from different coats. 
VRPs expressing the SARS-CoV spike glycoprotein from VEE virus 3000, 3014, or 3526 coat were 
constructed as previously described and assembled under identical conditions (11, 17). For packaging 
VRP 3526, genes encoding the capsid and envelope proteins were synthesized from BioBasic, Inc., and 
were inserted into pSMART vectors (Lucigen Inc.). VRP construct expressing SARS-CoV S glycoprotein was 
generated using overlap PCR by fusing an amplicon containing the S gene in frame with an amplicon 
containing sequences from the VEE virus replicon. The primers for the VEE virus replicon and the primers 
used for generating the S gene amplicon were described previously (41). VRP-HA utilizes the V3000 coat 
and was generated as previously described (17). Ligated DNA was digested with ApaI and PacI and 
inserted into the pVR21 plasmid. VRPs were packaged using helper RNAs encoding structural proteins as 
described before (41).
Generation of polyclonal mouse antisera, neutralization assays, and Western blot analysis. 
Five-week-old mice were primed and boosted with 105 infectious units (IU) of the VRPs. Following 
vaccination, mouse polyclonal sera were generated from BALB/c mice as described previously (17). 
Neutralization assays using mouse antisera involving SARS-CoV were performed as described previously 
(17). For Western blotting, lysates from cells infected with VRP 3526 S or VRP 3000 S were prepared as 
described before in detail (42), and these blots were probed using the indicated mouse polyclonal sera.
V.D.M.) and the Wellcome Trust (A17-0915-001 to R.S.B.).
Mice immunizations and challenge with lethal SARS-CoV challenge. Ten and 50 2-week-old 
female (BALB/c) mice were primed at 5 weeks or 12 months of age, respectively, with 1  105 IU of each 
respective VRP or mock vaccinated with phosphate-buffered saline (PBS) as a control. Titers of VRP were 
determined in Vero cells using antisera against the replicase proteins. Mice were monitored for 7 days 
after prime to ensure that unexpected complications (e.g., virus-induced hind leg paralysis or enceph-
alitis) that could arise as a result of the generation of authentic VEE virus by recombinatory processes in 
vivo did not occur. Serum was collected by the tail nick method 21 days after prime (8, 17). The animals 
were boosted again with 1  105 IU of VRPs and monitored daily as described previously. Twenty-one 
days postboost, serum was again collected by tail nick for analysis. All of the animal immunizations were 
performed under BSL2 conditions. Animals were transferred and allowed to acclimatize for at least 1 
week in the BSL3 laboratory to avoid any stress prior to virus challenge. Animals were anesthetized with 
ketamine-xylazine mixture and intranasally infected with 105 PFU of rMA15 virus or rMA15 GD03 S in a 
50-l volume. Animals were weighed daily, and clinical symptoms of disease were monitored regularly. 
Animals that lost 20% of their body weight were euthanized according to the IACUC guidelines. Lung 
tissues were harvested 2 and 4 days postinfection to analyze viral titers, histopathology, and viral and 
host transcripts that change as a result of vaccination/challenge.
Determination of lung titers. Briefly, portions of the lung were weighed, placed in 0.5 ml Dulbecco’s 
PBS (DPBS), and frozen at 80°C until analyzed. Lungs were then homogenized in a Magna Lyzer (Roche) 
and clarified by centrifugation (12,000 rpm, 1 min in a microcentrifuge), and virus titers within lung 
supernatants were assessed via plaque assay in Vero E6 cells as described previously (8). Virus pathology 
was assessed as previously described by our group (43).
Pathological evaluations. Lungs harvested 2 and 4 days postinfection were fixed in 4% formalde-
hyde (formalin) for 7 days to ensure virus inactivation. The formalin was replaced using fresh formalin 
before the tissues were transferred out of BSL3 for processing under BSL2 conditions. The lung tissues 
were then embedded in paraffin, and cut tissue sections were stained with hematoxylin and eosin (H&E) 
to identify any immune infiltrates in the lung. Pathology from H&E-stained sections were blind scored for 
clinical disease features, including airway disease, vascular cuffing, pneumonia, and diffuse alveolar 
damage, on a scale of 0 to 3 (1, mild; 3, severe).
Norwalk virus-like-particles. To determine whether the VRP 3526 platform could produce sufficient 
protein for the production of VLP-based vaccines, the Norwalk virus ORF2 gene was inserted directly into 
the VEE virus replicon vector for the production of VRPs as previously described (17). VLPs were 
expressed in VRP-infected BHK cells and purified by velocity sedimentation in sucrose, followed by 
simultaneous concentration and dialysis into PBS using 100-kDa-cutoff centrifugal filter units (Millipore)
(44).
EIAs. Mouse anti-Norwalk virus VLP polyclonal serum reactivity to Norwalk virus VLPs was deter-
mined by enzyme immunoassay (EIA) (45). Briefly, plates were coated with decreasing concentrations of 
VLP in PBS before the addition of 0.2% serum. Primary antibody incubation was followed by anti-mouse 
IgG-horseradish peroxidase (HRP) (GE Healthcare) and color development with one-step ultra TMB ELISA 
HRP substrate solution (Thermo-Fisher). Each step was followed by washing with PBS– 0.05% Tween 20, 
and all antibodies were diluted in 5% dry milk in PBS– 0.05% Tween 20. The percent maximum binding 
was defined as the binding level (optical density at 450 nm) at a given VLP concentration divided by the 
binding level of 1 g/ml VLP multiplied by 100. Data were fit with sigmoidal dose-response curves in 
Prism 6 (GraphPad), and EC50s were calculated. EC50s between VLPs generated from different VRP coats 
were compared using a Student’s t test. A difference was considered significant if the P value was 0.05.
VLP-carbohydrate ligand-binding assays. Pig gastric mucin type III (PGM; Sigma Chemicals) was 
solvated in PBS at 5 mg/ml, coated onto EIA plates at 10 g/ml in PBS for 4 h, and blocked overnight 
at 4°C in 5% dry milk in PBS– 0.05% Tween 20 before decreasing concentrations of Norwalk virus VLPs 
were added for 1 h. Bound VLPs were detected by a mouse anti-Norwalk VLP monoclonal antibody at 2 
g/ml followed by anti-mouse IgG-HRP (GE Healthcare), and color was developed with one-step ultra 
TMB ELISA HRP substrate solution (Thermo-Fisher). All incubations were done at room temperature. Each 
step was followed by washing with PBS– 0.05% Tween 20, and all reagents were diluted in 5% dry milk 
in PBS– 0.05% Tween 20. Data were analyzed as described above for EIAs.
Statistical approaches. Statistical analysis was performed using Prism (GraphPad, San Diego, CA) 
software. Nonparametric Mann-Whitney or Student’s t tests were performed to generate P values as 
noted in the text.
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